Especially in HER2-positive breast cancer, the upregulation of HER3 was detected in response to PI3K inhibition (Chakrabarty et al., 2012; Chandarlapaty et al., 2011; Garrett et al., 2011, 2013; Tao et al., 2014). Here, ERBB3 is linked to breast carcinoma.